Clinical trial
Clinical on the Safety and Effectiveness of Fosaprepitant Dimeglumine for Injection in the Prevention of Nausea and Vomiting Caused by Tumor Chemotherapy Drugs.
NCT05755659 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Clinical on the Safety and Effectiveness of Fosaprepitant Dimeglumine for Injection in the Prevention of Nausea and Vomiting Caused by Tumor Chemotherapy Drugs.
- Lead sponsor
- Xijing Hospital
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- July 15, 2022
- Completion date
- December 20, 2024
- Enrollment
- 3,000 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.